Exhibit
      33.1





CERTIFICATION
      PURSUANT TO RULE 13A-14 OR 15D-14 OF THE


SECURITIES
      EXCHANGE ACT 1934,


AS
      ADOPTED PURSUANT TO SECTION 302


OF
      THE
      SARBANNES-OXLEY ACT OF 2002





I,
      James
      F. Mongiardo, certify that:





1.
      I have
      reviewed this quarterly report on Form 10QSB of RegenoCELL Therapeutics, Inc.
      (formerly Good Buddy’s Coffee Express, Inc.);





2.
      Based
      upon my knowledge, this quarterly report does not contain any untrue statement
      of a material fact or omit to state a material fact necessary to make the
      statements made, in light of the circumstances under which such statements
      were
      made, not misleading with respect to the period covered by this quarterly
      report;





3.
      Based
      upon my knowledge, the financial statements, and other financial information
      included in this quarterly report, fairly present in all material respects
      the
      financial condition, results of operations and cash flows of the registrant
      as
      of, and for, the periods presented in this quarterly report;





4.
      I am
      responsible for establishing and maintaining disclosure controls and procedures
      (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) ) and internal control
      over financial reporting (as defined in Exchange Act Rules 13a-15 (f) and 15d-
      15 (f) ) for the registrant and have:





a.
      designed such disclosure controls and procedures, or caused such disclosure
      controls and procedures to be designed under our supervision, to ensure that
      material information relating to the registrant, including its consolidated
      subsidiaries, is made known to me by others within those entities, particularly
      during the period in which this quarterly report is being prepared;





b.
      designed such internal control over financial reporting, or caused such internal
      control over financial reporting to be designed under our supervision, to
      provide reasonable assurance regarding the reliability of financial reporting
      and the preparation of financial statements for external purposes in accordance
      with generally accepted accounting purposes;





c.
      evaluated the effectiveness of the registrant’s disclosure controls and
      procedures and presented in this report our conclusions about the effectiveness
      of the disclosure controls and procedures, as of the end of the period covered
      by this quarterly report based upon such evaluation; and





d.
      disclosed in this quarterly report any change in the registrant’s internal
      control over financial reporting that occurred during the registrant’s most
      recent fiscal quarter that has materially affected, or is reasonably likely
      to
      materially affect, the registrant’s internal control over financial reporting;
      and









5.
      I have
      disclosed, based on my most recent evaluation of internal control over financial
      reporting, to the registrant’s auditors and the audit committee of registrant’s
      board of directors (or persons performing the equivalent
      functions):





a.
      all
      significant deficiencies and material weaknesses in the design or operation
      of
      internal control over financial reporting which are reasonably likely to
      adversely affect the registrant’s ability to record, process, summarize and
      report financial information; and





b.
      any
      fraud, whether or not material, that involves management or other employees
      who
      have a significant role in the registrant’s internal control over financial
      reporting.





Dated:
      August 15, 2008


By:
            /s/James
              F. MongiardoJames
              F. MongiardoChief Executive Officer
              and
              Chief Financial Officer